Company Overview
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical entity focused on the development and commercialization of therapies designed for the prevention and treatment of infectious diseases within the United States market. The company specifically offers Arakoda, a product utilized for malaria preventative treatment, positioning it within the broader biotechnology industry which is characterized by high innovation potential but also significant regulatory and development risks. This enterprise functions within the healthcare sector, an essential domain that provides critical services and products to the population but often involves substantial capital expenditure for research and development. The company's current scale is defined by a market capitalization of $3.71M and a trailing twelve-month revenue of $1.36M, supported by an operational team of 3 employees. These financial figures indicate that the company is a micro-cap entity with a very small market presence relative to established large-cap pharmaceutical peers, suggesting a nascent stage of commercialization where revenue generation is still scaling from a limited product portfolio.
Financial Health
The company reported revenue of $1.36M over the trailing twelve-month period, yet this revenue generated a net loss of $-8,475,564, revealing a cost structure where expenses significantly outpace income. The EBITDA stands at $-7,831,017, further highlighting the heavy operational burn rate typical of early-stage biotechnology firms before products achieve widespread market adoption. Free cash flow is recorded at $-3,976,114, indicating that the company is currently consuming cash reserves to fund operations and development rather than generating surplus liquidity. The gross margin is 42.9%, which suggests that the cost of goods sold is relatively contained compared to sales, though the operating margin of -440.0% and profit margin of 0.0% demonstrate severe inefficiencies in overhead management or high research and development costs relative to revenue. On the balance sheet, the company holds $4.12M in cash against a debt obligation of $153,764, creating a debt-to-equity ratio of 3.54 which implies a leveraged position despite the low absolute debt amount. The current ratio is 2.87, indicating that the company possesses sufficient current assets to cover its short-term liabilities with nearly three times the necessary liquidity. Return on Equity is -154.8% and Return on Assets is -70.0%, metrics that reveal management is currently unable to generate positive returns on the capital invested or the assets owned, a common characteristic for loss-making biotech firms.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the net loss, while the forward P/E is listed as -0.19, implying that analysts or market data sources project continued earnings negative trajectories rather than a transition to profitability in the immediate forward period. The price-to-book ratio is -0.30, a negative figure that indicates the market is valuing the company at less than the net book value of its assets, often seen when liabilities exceed the tangible value of assets or when intangible assets are not fully reflected on the balance sheet. The price-to-sales ratio is 2.72, suggesting the market is assigning a premium to the company's revenue stream despite the lack of profitability, which is common in biotech valuation models that focus on pipeline potential rather than current earnings. The EV/EBITDA is -0.91, another negative multiple that reinforces the company's unprofitable status and the difficulty in applying traditional enterprise value metrics to a cash-burning entity. The stock has exhibited significant price volatility with a 52-week high of $17.68 and a 52-week low of $1.32, meaning the current price sits at a level that reflects high uncertainty and potential for wide swings based on clinical trial results or partnership announcements.
Growth & Income
Revenue growth is reported at 256.9% year-over-year, demonstrating a massive expansion in sales, while earnings growth is N/A because the company continues to report net losses. Since earnings growth cannot be calculated against zero or negative earnings in a standard percentage sense, the disparity between the high revenue growth and negative earnings suggests that the company is rapidly expanding its top line while simultaneously managing substantial costs that are preventing profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all of its earnings, if any, or rather, reinvests its capital and cash reserves directly into research, development, and commercialization efforts rather than distributing income to shareholders. This growth and income profile characterizes the company as a pure-play speculative investment where capital appreciation is the only potential return, relying entirely on the successful commercialization of its infectious disease therapies to eventually transition from a cash consumer to a cash generator.